secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpringWorks Therapeutics, Inc. (—)
CIK:        0001773427
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001773427-24-000016
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SpringWorks Q1 OGSIVEO revenue $21M; net loss widens to $87.4M
--------------------------------------------------------------

- OGSIVEO net product revenue $21.0M in first full quarter of U.S. launch.
- Net loss $87.4M ($1.18 per share) vs. $73.4M ($1.18 per share) in Q1 2023, driven by higher SG&A and R&D costs.
- Cash, equivalents and marketable securities $573.0M as of March 31, 2024.
- EMA validated MAA for nirogacestat in desmoid tumors; rolling NDA submission for mirdametinib in NF1-PN initiated.
- Phase 2b ReNeu trial results accepted for oral presentation at 2024 ASCO Annual Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1773427/000177342724000016/0001773427-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1773427/000177342724000016/swtx-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001773427-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer